Eli Crane Voted Against Expanding Public Health Programs Addressing Arizona’s Opioid Crisis
Crane Voted Against Reauthorizing Public Health Programs Addressing Opioid Use Disorders And Against Requiring Medicaid To Cover Medication-Assisted Treatment For Opioid Use Disorder
Crane Voted Against Reauthorizing, Through FY 2028, Public Health Programs Addressing Opioid Use Disorders And Other Aspects Of Mental Health. In December 2023, Crane voted against: “Guthrie, R-Ky., motion to suspend the rules and pass the bill, as amended, that would reauthorize, through fiscal 2028, a number of public health programs that address opioid use disorders and other aspects of mental health. It would modify federal Controlled Substances Schedules by defining xylazine as a Schedule III substance and by requiring the Health and Human Services Department to determine if products containing a combination of buprenorphine and naloxone should be placed on the controlled substances schedule. The bill would also require Medicaid to permanently cover all forms of medication-assisted treatment for opioid use disorder, permanently lifts the Medicaid exclusion for treatment of substance use disorder in institutions for mental diseases, and generally prohibits states from terminating an individual's enrollment in Medicaid or CHIP due to incarceration. Among other provisions, it would, as an offset, permanently extend the existing rate of additional federal funding to states for electing to apply a minimum medical loss ratio for their Medicaid managed care organizations.” The motion was agreed to by a vote of 386-37. [H.R. 4531, Vote #715, 12/12/23; CQ, 12/12/23]
Crane Voted Against A Bill That Would Require Medicaid To Permanently Cover All Forms Of Medication-Assisted Treatment For Opioid Use Disorder. In December 2023, Crane voted against: “Guthrie, R-Ky., motion to suspend the rules and pass the bill, as amended, that would reauthorize, through fiscal 2028, a number of public health programs that address opioid use disorders and other aspects of mental health. It would modify federal Controlled Substances Schedules by defining xylazine as a Schedule III substance and by requiring the Health and Human Services Department to determine if products containing a combination of buprenorphine and naloxone should be placed on the controlled substances schedule. The bill would also require Medicaid to permanently cover all forms of medication-assisted treatment for opioid use disorder, permanently lifts the Medicaid exclusion for treatment of substance use disorder in institutions for mental diseases, and generally prohibits states from terminating an individual's enrollment in Medicaid or CHIP due to incarceration. Among other provisions, it would, as an offset, permanently extend the existing rate of additional federal funding to states for electing to apply a minimum medical loss ratio for their Medicaid managed care organizations.” The motion was agreed to by a vote of 386-37. [H.R. 4531, Vote #715, 12/12/23; CQ, 12/12/23]
Crane Voted Against A Bill That Would Permanently Lift The Medicaid Exclusion For Treatment Of Substance Use Disorder In Institutions For Mental Diseases. In December 2023, Crane voted against: “Guthrie, R-Ky., motion to suspend the rules and pass the bill, as amended, that would reauthorize, through fiscal 2028, a number of public health programs that address opioid use disorders and other aspects of mental health. It would modify federal Controlled Substances Schedules by defining xylazine as a Schedule III substance and by requiring the Health and Human Services Department to determine if products containing a combination of buprenorphine and naloxone should be placed on the controlled substances schedule. The bill would also require Medicaid to permanently cover all forms of medication-assisted treatment for opioid use disorder, permanently lifts the Medicaid exclusion for treatment of substance use disorder in institutions for mental diseases, and generally prohibits states from terminating an individual's enrollment in Medicaid or CHIP due to incarceration. Among other provisions, it would, as an offset, permanently extend the existing rate of additional federal funding to states for electing to apply a minimum medical loss ratio for their Medicaid managed care organizations.” The motion was agreed to by a vote of 386-37. [H.R. 4531, Vote #715, 12/12/23; CQ, 12/12/23]
Arizona Faced An Opioid Crisis, Recording More Than 4,000 Overdoses In 2023
The Arizona Department of Education: “Arizona Is Facing An Opioid Overdose Epidemic, Claiming Five Lives Per Day.” “Arizona is facing an opioid overdose epidemic, claiming five lives per day. Among all age groups, Arizona recorded more than 1800 opioid-related deaths and more than 4,000 overdoses in 2023. Citing the growing incidents of Fentanyl deaths and overdoses among Arizona school-aged children, schools chief Tom Horne has announced an initiative to supply schools with the anti-overdose drug Narcan and the creation of a statewide task force to address this growing crisis.” [The Arizona Department of Education, accessed on 7/8/25]
The Arizona Department Of Education: “Among All Age Groups, Arizona Recorded More Than 1,800 Opioid-Related Deaths And More Than 4,000 Overdoses In 2023.” “Arizona is facing an opioid overdose epidemic, claiming five lives per day. Among all age groups, Arizona recorded more than 1800 opioid-related deaths and more than 4,000 overdoses in 2023. Citing the growing incidents of Fentanyl deaths and overdoses among Arizona school-aged children, schools chief Tom Horne has announced an initiative to supply schools with the anti-overdose drug Narcan and the creation of a statewide task force to address this growing crisis.” [The Arizona Department of Education, accessed on 7/8/25]
KFF: “In 2021, There Were 2,000 Opioid Overdose Deaths In Arizona, Which Accounted For 73% Of All Drug Overdose Deaths In The State.” “In 2021, there were 2,000 opioid overdose deaths in Arizona, which accounted for 73% of all drug overdose deaths in the state. Across the U.S., opioid overdose deaths accounted for 75% of all drug overdose deaths in the country in 2021. As shown in the figure below, from 2011 to 2021, the age-adjusted death rate due to opioid overdose increased from 8.8 per 100,000 to 28.8 per 100,000 in Arizona. Over the same period, the age-adjusted death rate increased from 7.3 per 100,000 to 24.7 per 100,000 in the U.S.” [Kaiser Family Foundation, accessed on 7/8/25]
KFF: “From 2011 To 2021, The Age-Adjusted Death Rate Due To Opioid Overdose Increased From 8.8 Per 100,000 To 28.8 Per 100,000 In Arizona.” “In 2021, there were 2,000 opioid overdose deaths in Arizona, which accounted for 73% of all drug overdose deaths in the state. Across the U.S., opioid overdose deaths accounted for 75% of all drug overdose deaths in the country in 2021. As shown in the figure below, from 2011 to 2021, the age-adjusted death rate due to opioid overdose increased from 8.8 per 100,000 to 28.8 per 100,000 in Arizona. Over the same period, the age-adjusted death rate increased from 7.3 per 100,000 to 24.7 per 100,000 in the U.S.” [Kaiser Family Foundation, accessed on 7/8/25]
Image: see original report, p. 31
[Kaiser Family Foundation, accessed on 7/8/25]